Page last updated: 2024-11-05

methacrylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Methacrylamide is a monomer used in the production of polymethacrylamide, a synthetic polymer with a wide range of applications. It is typically synthesized by the dehydration of N-methylacetamide with phosphorus pentoxide. Polymethacrylamide has been investigated for its use in various fields, including water treatment, drug delivery, and tissue engineering. It exhibits excellent water solubility and biocompatibility, making it a promising material for biomedical applications. Research efforts are focused on exploring its potential for controlled drug release, wound healing, and tissue regeneration. Methacrylamide is also a precursor to other important compounds, such as methacryloyl chloride, which is used in the production of various polymers and resins.'

Cross-References

ID SourceID
PubMed CID6595
CHEMBL ID158237
CHEBI ID51759
MeSH IDM0133443

Synonyms (72)

Synonym
nsc-24147
methacrylamide
2-propenamide, 2-methyl-
wln: zvy1&u1
methacryamide
.alpha.-methyl acrylic amide
nsc24147
methacrylic acid amide
2-methylacrylamide
methylacrylic amide
nsc23772
2-methylpropenamide
usaf rh-1
nsc-23772
methacrylic amide
79-39-0
inchi=1/c4h7no/c1-3(2)4(5)6/h1h2,2h3,(h2,5,6
NCGC00091557-01
caswell no. 549
alpha-methyl acrylic amide
mhoromer bm801
ai3-15660
ccris 4230
epa pesticide chemical code 052901
brn 0605397
amid kyseliny methakrylove [czech]
einecs 201-202-3
nsc 23772
methacrylamide, 98%
2-methylprop-2-enamide
CHEBI:51759 ,
MLS002454414
smr001262239
2-methyl-acrylamide
CHEMBL158237 ,
M0077
AKOS000121166
NCGC00091557-03
NCGC00091557-02
NCGC00259830-01
NCGC00253927-01
tox21_300001
tox21_202281
dtxsid8029600 ,
cas-79-39-0
dtxcid109600
BBL011416
STL146522
ec 201-202-3
amid kyseliny methakrylove
unii-k67ng89j77
k67ng89j77 ,
FT-0613002
2-methyl-2-propenamide
methacrylamide [inci]
alpha-methylacrylamide
methyl acrylamide
mfcd00008018
methacrylamide, purum, >=98.0% (hplc)
F0001-2076
bdbm50226194
Q1549805
SY010261
2-methyl-2-propenamid
A914288
methacrylamide 2-methylpropenamide
E80423
HY-W020027
CS-0031911
25014-12-4
EN300-28218
2-methylpropenoic acid amide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The maternal no-observed adverse effect level (NOAEL) was 60 mg/kg/day."( Evaluation of the developmental toxicity of methacrylamide and N,N'-methylenebisacrylamide in Swiss mice.
George, JD; Heindel, JJ; Marr, MC; Myers, CB; Price, CJ; Schwetz, BA, 1998
)
0.56
" Remarkably, monthly P-Dex administration (dose equivalent to free Dex treatment) was equally effective as free dexamethasone, but was not associated with systemic bone loss (a major adverse side effect of glucocorticoids)."( Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects.
Dusad, A; Fehringer, EV; Garvin, KL; Goldring, SR; Purdue, PE; Ren, K; Wang, D; Yuan, F; Yuan, H, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Tissue radioactivity 24 h after IV dosing was high in blood, liver and serum, and low in brain, nerve and muscle."( Percutaneous absorption of [14C]methacrylamide in animals.
Hashimoto, K; Tanii, H, 1985
)
0.55
" The last litter was reared and dosed after weaning until mating at 74 +/- 10 days of age with the same level of compound given to the parents Neurotoxicity was assessed at several times in both generations by measuring forelimb and hindlimb grip strength."( The reproductive and neural toxicities of acrylamide and three analogues in Swiss mice, evaluated using the continuous breeding protocol.
Chapin, RE; Collins, BJ; Fail, PA; George, JD; Grizzle, TB; Harry, GJ; Heindel, JJ; Teague, J, 1995
)
0.29
"Most treatments for diabetic eye conditions rely on systemic (oral) or intravitreal administration, and there is still a demand of efficient and comfortable ocular dosage forms."( Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications.
Alvarez-Lorenzo, C; Alvarez-Rivera, F; Concheiro, A, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
acrylamidesAn enamide which is acrylamide or a derivative of acrylamide obtained by replacement of one or more of its hydrogens.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.28180.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency14.12540.004023.8416100.0000AID485290
GLI family zinc finger 3Homo sapiens (human)Potency43.62940.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency48.95300.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.64730.001530.607315,848.9004AID1224841; AID1224842
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.06520.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alcohol dehydrogenase E chainEquus caballus (horse)Ki954.99300.14122.89278.7000AID33855
Alcohol dehydrogenase S chainEquus caballus (horse)Ki954.99300.14122.89278.7000AID33855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID33855Inhibitory activity against horse liver alcohol dehydrogenase (ADH)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
AID23467Partition coefficient (logP)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (239)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.26)18.7374
1990's14 (5.86)18.2507
2000's36 (15.06)29.6817
2010's133 (55.65)24.3611
2020's53 (22.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.85 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index68.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other247 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]